Achieve Life Sciences, Inc. (ACHV)

Market Cap	185.81M +83.4%
Revenue (ttm)	n/a
Net Income	-54.65M
EPS	-1.25
Shares Out	53.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	570,443
Open	3.330
Previous Close	3.320
Day's Range	3.300 - 3.490
52-Week Range	1.950 - 6.025
Beta	1.96
Analysts	Strong Buy
Price Target	15.50 (+344.13%)
Earnings Date	May 12, 2026

About ACHV

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Richard A. Stewart
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHV
• Website: https://www.achievelifesciences.com

Analyst Summary

According to 2 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 344.13% from the latest price.

Price Target

$15.5

(344.13% upside)

Analyst Consensus: Strong Buy